China Universal Asset Management Company’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.5M Sell
13,091
-1,397
-10% -$120K 0.09% 160
2026
Q1
$1.21M Sell
14,488
-10,036
-41% -$795K 0.09% 167
2025
Q4
$1.91M Buy
24,524
+1,992
+9% +$135K 0.15% 117
2025
Q3
$1.28M Sell
22,532
-547
-2% -$24.7K 0.11% 152
2025
Q2
$1.01M Buy
23,079
+10,052
+77% +$346K 0.09% 165
2025
Q1
$357K Sell
13,027
-706
-5% -$25.7K 0.03% 271
2024
Q4
$552K Buy
13,733
+1,311
+11% +$59.2K 0.05% 241
2024
Q3
$588K Buy
12,422
+5,214
+72% +$230K 0.06% 199
2024
Q2
$215K Sell
7,208
-4,545
-39% -$157K 0.03% 230
2024
Q1
$472K Buy
11,753
+5,330
+83% +$191K 0.06% 187
2023
Q4
$164K Buy
6,423
+5,002
+352% +$89.5K 0.03% 222
2023
Q3
$19.8K Buy
1,421
+696
+96% +$14K 0.01% 300
2023
Q2
$16.7K Sell
725
-23
-3% -$659 0.01% 283
2023
Q1
$22.2K Buy
748
+191
+34% +$6.16K 0.01% 206
2022
Q4
$13.9K Buy
557
+72
+15% +$1.92K 0.01% 201
2022
Q3
$11K Buy
+485
New +$12.8K ﹤0.01% 197

Other funds holding KYMR

China Universal Asset Management Company's KYMR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Kymera Therapeutics (KYMR) stake by 9.6% in Q2 2026, selling an estimated $120K and leaving 13,091 shares worth $1.5M. The position accounts for 0.09% of the portfolio, ranked #160.

China Universal Asset Management Company first reported a position in KYMR in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.91M in Q4 2025. 49 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • China Universal Asset Management Company held 13,091 shares of Kymera Therapeutics worth $1.5M as of Q2 2026.
  • China Universal Asset Management Company sold 1,397 Kymera Therapeutics shares in Q2 2026, an estimated $120K.
  • Kymera Therapeutics made up 0.09% of China Universal Asset Management Company's portfolio in Q2 2026, its #160 holding.
  • China Universal Asset Management Company first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Kymera Therapeutics position peaked at $1.91M in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.